Literature DB >> 5857619

A follow-up of patients diagnosed as suffering from "hysteria".

E T Slater, E Glithero.   

Abstract

Entities:  

Mesh:

Year:  1965        PMID: 5857619     DOI: 10.1016/0022-3999(65)90004-8

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


× No keyword cloud information.
  25 in total

1.  Multiple sclerosis masquerade.

Authors:  S Hunyi; G Nanayakkara
Journal:  Br J Gen Pract       Date:  2001-06       Impact factor: 5.386

2.  Somatization Disorder.

Authors:  Donald M. Hilty; James A. Bourgeois; Celia H. Chang; Mark E. Servis
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

Review 3.  [Conversion disorders. From neurobiology to treatment].

Authors:  C Schönfeldt-Lecuona; B J Connemann; A Höse; M Spitzer; H Walter
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

4.  Psychologists' sensitivity to medical factors examined during standard psychological evaluations: A preliminary description.

Authors:  J D Meyer; C M Fink
Journal:  J Clin Psychol Med Settings       Date:  1995-12

5.  Factors in the diagnosis and treatment of chronic pain.

Authors:  A Taub
Journal:  J Autism Child Schizophr       Date:  1975-03

6.  Psychogenic movement disorders.

Authors:  Elizabeth L Peckham; Mark Hallett
Journal:  Neurol Clin       Date:  2009-08       Impact factor: 3.806

7.  Prognosis of symptoms that are medically unexplained. Every neurology service should have access to specialist liaison psychiatry.

Authors:  M Götz; A House
Journal:  BMJ       Date:  1998-08-22

8.  Hysteria: a case for conservation?

Authors:  G G Lloyd
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-15

9.  Detection of ophthalmoscopically occult maculopathy by focal electroretinography.

Authors:  E T Schmeisser; A D Epstein
Journal:  Doc Ophthalmol       Date:  2001-11       Impact factor: 2.379

10.  [Conversion disorders].

Authors:  C Fricke-Neef; C Spitzer
Journal:  Nervenarzt       Date:  2013-03       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.